CSPC Pharmaceutical Group Resultados de beneficios anteriores

Pasado controles de criterios 2/6

CSPC Pharmaceutical Group ha aumentado sus beneficios a una tasa media anual de 13%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento de 5.9% anual. Los ingresos han ido creciendo a una tasa media de 10.9% al año. La rentabilidad financiera de CSPC Pharmaceutical Group es de 17.3%, y sus márgenes netos son de 18.7%.

Información clave

13.0%

Tasa de crecimiento de los beneficios

13.2%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	5.6%
Tasa de crecimiento de los ingresos	10.9%
Rentabilidad financiera	17.3%
Margen neto	18.7%
Última actualización de beneficios	31 Dec 2023

Actualizaciones de resultados anteriores recientes

Recent updates

CSPC Pharmaceutical Group (HKG:1093) Will Pay A Dividend Of CN¥0.14

Apr 29

There's Reason For Concern Over CSPC Pharmaceutical Group Limited's (HKG:1093) Price

Apr 22

CSPC Pharmaceutical Group's (HKG:1093) Dividend Will Be CN¥0.14

Apr 01

CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 49% Below Their Intrinsic Value Estimate

Jan 22

Some Confidence Is Lacking In CSPC Pharmaceutical Group Limited's (HKG:1093) P/E

Jan 04

Are Investors Undervaluing CSPC Pharmaceutical Group Limited (HKG:1093) By 36%?

Oct 22

Is CSPC Pharmaceutical Group (HKG:1093) A Risky Investment?

Sep 21

CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 62% Above Its Share Price

Jul 09

Does CSPC Pharmaceutical Group (HKG:1093) Have A Healthy Balance Sheet?

Jun 20

CSPC Pharmaceutical Group's (HKG:1093) Shareholders Will Receive A Bigger Dividend Than Last Year

Jun 01

CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To CN¥0.11

Apr 04

CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 92% Above Its Share Price

Mar 12

We Think CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt With Ease

Dec 26

CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 98% Above Its Share Price

Oct 18

CSPC Pharmaceutical Group (HKG:1093) Could Easily Take On More Debt

Sep 15

CSPC Pharmaceutical Group (HKG:1093) Will Pay A Larger Dividend Than Last Year At CN¥0.10

Aug 26

CSPC Pharmaceutical Group (HKG:1093) Will Pay A Larger Dividend Than Last Year At HK$0.10

May 27

CSPC Pharmaceutical Group (HKG:1093) Has Announced That It Will Be Increasing Its Dividend To HK$0.10

Apr 27

CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To HK$0.10

Apr 04

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero CSPC Pharmaceutical Group. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

SEHK:1093 Ingresos, gastos y beneficios (CNY Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	31,450	5,873	10,330	4,830
30 Sep 23	31,306	6,118	10,410	4,744
30 Jun 23	31,407	6,092	10,973	4,406
31 Mar 23	31,116	6,116	11,177	4,093
31 Dec 22	30,937	6,091	11,510	3,987
30 Sep 22	30,721	5,738	11,915	3,845
30 Jun 22	29,655	5,509	11,611	3,704
31 Mar 22	29,007	5,538	11,700	3,643
31 Dec 21	27,867	5,605	11,453	3,433
30 Sep 21	26,369	5,977	10,747	3,132
30 Jun 21	26,175	5,908	10,703	3,050
31 Mar 21	25,551	5,472	10,332	3,013
31 Dec 20	24,942	5,160	10,323	2,890
30 Sep 20	24,558	4,421	10,522	2,765
30 Jun 20	23,515	4,150	10,287	2,511
31 Mar 20	22,735	3,922	10,050	2,108
31 Dec 19	22,103	3,714	9,461	2,000
30 Sep 19	21,335	3,625	8,887	1,928
30 Jun 19	20,135	3,454	8,202	1,725
31 Mar 19	18,835	3,294	7,426	1,543
31 Dec 18	17,717	3,081	6,841	1,342
30 Sep 18	16,877	2,905	6,337	1,346
30 Jun 18	15,729	2,734	5,664	973
31 Mar 18	13,959	2,443	4,839	912
31 Dec 17	12,877	2,307	4,178	679
30 Sep 17	12,203	2,195	3,747	277
30 Jun 17	11,659	2,068	3,410	282
31 Mar 17	11,383	1,979	3,203	0
31 Dec 16	11,075	1,881	2,992	0
30 Sep 16	10,439	1,711	2,725	0
30 Jun 16	10,118	1,607	2,576	0
31 Mar 16	9,656	1,473	2,419	0
31 Dec 15	9,545	1,395	2,347	0
30 Sep 15	9,284	1,305	2,202	0
30 Jun 15	9,072	1,192	2,045	0
31 Mar 15	8,919	1,126	1,938	0
31 Dec 14	8,762	1,015	1,871	0
30 Sep 14	8,423	896	1,748	0
30 Jun 14	8,197	849	1,686	0
31 Mar 14	8,001	814	1,627	0
31 Dec 13	7,768	760	1,500	0
30 Sep 13	7,345	1,967	1,398	0
30 Jun 13	6,156	1,927	1,212	0

Ingresos de calidad: 1093 tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio(18.7%) de 1093 son inferiores a los del año pasado (19.7%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de 1093 han crecido un 13% al año en los últimos 5 años.

Acelerando crecimiento: 1093 ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: 1093 tuvo un crecimiento negativo de los beneficios (-3.6%) durante el año pasado, lo que dificulta la comparación con la media de la industria Pharmaceuticals (1.3%).

Rentabilidad financiera

Alta ROE: La rentabilidad financiera de 1093 (17.3%) se considera baja.

CSPC Pharmaceutical Group Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Información clave

Actualizaciones de resultados anteriores recientes

Full year 2023 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings: EPS and revenues miss analyst expectations

CSPC Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024

Third quarter 2023 earnings: Revenues and EPS in line with analyst expectations

CSPC Pharmaceutical Group Limited to Report Nine Months, 2023 Results on Nov 30, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Recent updates

CSPC Pharmaceutical Group (HKG:1093) Will Pay A Dividend Of CN¥0.14

CSPC Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

CSPC Pharmaceutical Group Limited Announces Highly Selective Mat2A Inhibitor (SYH2039) Obtains Clinical Trial Approval in the U.S

There's Reason For Concern Over CSPC Pharmaceutical Group Limited's (HKG:1093) Price

Executive Chairman exercised options to buy HK$52m worth of stock.

CSPC Pharmaceutical Group's (HKG:1093) Dividend Will Be CN¥0.14

CSPC Pharmaceutical Group Limited Announces Dapagliflozin Tablets Obtains Drug Registration Approval

CSPC Pharmaceutical Group Limited, Annual General Meeting, May 28, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

CSPC Pharmaceutical Group Limited Announces Antibody-Drug Conjugate SYS6023 Obtains Clinical Trial Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 26 June 2024

CSPC Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024

CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 49% Below Their Intrinsic Value Estimate

CSPC Pharmaceutical Group Limited's Bispecific Fusion Protein Drug JMT106 Obtains Clinical Trial Approval from the U.S. Food and Drug Administration

Some Confidence Is Lacking In CSPC Pharmaceutical Group Limited's (HKG:1093) P/E

CSPC Pharmaceutical Group Limited Announces Submission of New Drug Application for Irinotecan Liposome Injection to U.S. FDA

CSPC Pharmaceutical Group Limited Obtains Approval for Dextromethorphan Hydrobromide and Quinidine Sulphate Orally Disintegrating Tablets

CSPC Pharmaceutical Group Limited Announces Bivalent Covid-19 MRNA Vaccine (SYS6006.32) Included for Emergency Use in China

Third quarter 2023 earnings: Revenues and EPS in line with analyst expectations

CSPC Pharmaceutical Group Limited Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited to Report Nine Months, 2023 Results on Nov 30, 2023

CSPC Pharmaceutical Group Limited's ALMB-0166 Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Phase II Clinical Trial Evaluating its Efficacy and Safety in Patients with Acute Ischemic Stroke in China

Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. Jointly Receive Breakthrough Therapy Designation on KN026 by CDE

CSPC Pharmaceutical Group Limited Obtains Approval Granted by the National Medical Products Administration of the People's Republic of China

CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval

Investor sentiment improves as stock rises 19%

CSPC Pharmaceutical Group Limited Announces NBL-028 for the Treatment of Advanced Tumors

Are Investors Undervaluing CSPC Pharmaceutical Group Limited (HKG:1093) By 36%?

Is CSPC Pharmaceutical Group (HKG:1093) A Risky Investment?

CSPC Pharmaceutical Group Limited Announces Biologic License Application Approval for Narlumosbart for Injection (JMT103) by the NMPA

Upcoming dividend of HK$0.14 per share at 4.7% yield

CSPC Pharmaceutical Group Limited Announces Semaglutide Injection Obtains Clinical Trial Approval

CSPC Pharmaceutical Group Limited Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China

CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2023, Payable on 12 October 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

CSPC Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 23, 2023

CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 62% Above Its Share Price

Cspc Pharmaceutical Group Limited Announces Biologic License Application of Batoclimab (Hbm9161)

CSPC Ouyi Pharmaceutical Co., Ltd. Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China

Does CSPC Pharmaceutical Group (HKG:1093) Have A Healthy Balance Sheet?

CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval Granted by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

Cspc Pharmaceutical Group Limited Announces That Clinical Trial Application for Cpo301

Elevation Oncology Inc. Together with CSPC Pharmaceutical Group Limited Announce Promising Initial Clinical Data for SYSA1801 (EO-3021) from the Ongoing Phase 1 Dose Escalation and Expansion Study in China

Elevation Oncology Highlights First-In-Human Phase 1 Sysa1801 (Eo-3021) Clinical Data to Be Presented by Partner Cspc Pharmaceutical Group Limited At Asco 2023

CSPC Pharmaceutical Group's (HKG:1093) Shareholders Will Receive A Bigger Dividend Than Last Year

CSPC Pharmaceutical Group Limited Declares Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.11 per share at 3.1% yield

First quarter 2023 earnings: EPS and revenues miss analyst expectations

CSPC Pharmaceutical Group Limited to Report Q1, 2023 Results on May 25, 2023

CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To CN¥0.11

Executive Chairman recently bought HK$13m worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 92% Above Its Share Price

CSPC Pharmaceutical Group Limited Announces Highly Selective PRMT5 Inhibitor SYH2045 Obtains Clinical Trial Approval

Cspc Pharmaceutical Group Limited Announces ALMB-0166 for the Treatment of Osteoarthritis Obtains Clinical Trial Approval

CSPC Pharmaceutical Group Limited Receives Approval for SYH2043 from National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

We Think CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt With Ease

CSPC Pharmaceutical Group Limited Announces NBL-020 for the Treatment of Advanced Solid Tumors Obtains Clinical Trial Approval in the U.S

Cspc Pharmaceutical Group Limited Announces That Syh2055 Developed by the Group Has Obtained Approval Granted by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Announces Antibody-Drug Conjugate CPO204 Obtains Clinical Trial Approval in the U.S

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

CSPC Pharmaceutical Group Limited's SYHX1901 Tablets Obtains Approval Granted by the National Medical Products Administration

CSPC Pharmaceutical Group Limited Announces New Indication Application for Marketing Approval of Mingfule

CSPC Pharmaceutical Group Limited to Report Nine Months, 2022 Results on Nov 23, 2022

CSPC Pharmaceutical Group Limited Appoints Li Quan as an Independent Non-Executive Director

Investor sentiment improved over the past week

CSPC Pharmaceutical Group Limited Announces the Antibody-Drug Conjugate Sys6002

Desglose de ingresos y gastos
Beta